Hot on the heels of a positive PhIII, Immunocore hauls in $175M as it hunts its first TCR OK

Six weeks after Bahija Jallal’s crew at TCR pioneer Immunocore rolled out an upbeat presentation on their lead drug’s interim Phase III data, the biotech has scooped up an extra $175 million to back their prospective commercial launch.